Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2012 /
The WINTHER study

28th - 29th Jun 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 16.07.12
Views: 12335
Rating:

Prof Razelle Kurzrock - MD Anderson Cancer Center, Houston, USA

Prof Razelle Kurzrock explains how the WINTHER trial is using molecular data to determine which drugs specific patients should receive.

 

This large scale study will be carried out across four continents and include patients with all types of tumour.

 

The WINTHER trial will use both genetic sequencing in order to identify DNA mutations or abnormalities and RNA analysis to identify the appropriate treatment for patients who do not have recognised genetic abnormalities. 

 

Filming supported by Amgen

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation